Ablynx makes fresh start with ozoralizumab in Eddingpharm deal
This article was originally published in Scrip
Executive Summary
Ablynx has signed a deal with Chinese company Eddingpharm for certain Asian rights to its rheumatoid arthritis drug ozoralizumab, marking a fresh start after Pfizer backed out of a global deal in 2011.